Gaetz W, Saleh MG, Birnbaum C, Bloy L, Roberts TPL, Lynch DR. Myo-inositol elevation as an in vivo marker of reactive gliosis in pediatric Friedreich ataxia: evidence from HERMES-edited MR spectroscopy , Neuroimage: Clinical, 50:: 2026,103983.

Satoshi Miyashita, Anthony Zaki, Kaitlin Schlabach, Gabriel Kim, Juliane K. Vierecke, David Lynch, Carmela Tan, Eileen Hsich, Paulino Alvarez Advanced Heart Failure in Friedreich's Ataxia: A Story of Challenges, Opportunities, and Hope , JACC: Case Reports: 2026

Lin, K. Y., Bucha, A., McSweeney, K., Karaj, A., Tamaroff, J., Wade, K., O’Malley, S., Chung, N., Cilenti, N. A., Mesaros, C., Blair, I., Serai, S., Farmer, J., Bryant, K., Paridon, S. M., Putt, M., Zamani, P., Baur, J. A. Lynch, D. R., McCormack, S. E. Individualized exercise and NAD+ precursor supplementation in Friedreich’s Ataxia: a randomized controlled trial. , Lancet Neurol: 2026

Rummey C, Thomas-Black G, Garcia-Moreno H, Lynch DR, Abeti R, Arisoy H, Heslegrave A, Zetterberg H, Giunti P; European Friedreich's Ataxia Consortium for Translational Studies (EFACTS). Increase of Plasma Biomarkers in Friedreich's Ataxia: Potential Insights into Disease Pathology , Movement disorders, 409: 2025,1863-1873.

David R. Lynch, Angie Goldsberry, Christian Rummey, Jennifer Farmer, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Susan Perlman, Sub H. Subramony, George Wilmot, Theresa Zesiewicz, Lisa Weissfeld & Colin Meyer Propensity-matched analysis comparing omaveloxolone treatment to Friedreich ataxia natural history data: a plain language summary , Future Neurology: 2025

Georgiou-Karistianis N, Corben LA, Lock EF, Bujalka H, Adanyeguh I, Corti M, Deelchand DK, Delatycki MB, Dogan I, Farmer J, França MC Jr, Gabay AS, Gaetz W, Harding IH, Joers J, Lax MA, Li J, Lynch DR, Mareci TH, Martinez ARM, Pandolfo M, Papoutsi M, Parker RG, Reetz K, Rezende TJR, Roberts TP, Romanzetti S, Rudko DA, Saha S, Schulz JB, Subramony SH, Supramaniam VG, Lenglet C, Henry PG. Neuroimaging biomarkers for Friedreich ataxia: a cross-sectional analysis of TRACK-FA , Ann Neurol, 98(2): 2025,386-397

Perlman S, Zhang S, Setyawan J, Yang H, Jiang A, Hua Q, Boudreau J, Khan S, Bajaj A, Lynch DR, Lawson R. The clinical burden of Friedreich ataxia in the United States: A retrospective claims database analysis , J Neurol Sci, 475: 2025,123594.

Shiraishi DH, Saha S, Adanyeguh IM, Cocozza S, Corben LA, Deistung A, Delatycki MB, Dogan I, Gaetz W, Georgiou-Karistianis N, Graf S, Grisoli M, Henry PG, Jarola GM, Joers JM, Langkammer C, Lenglet C, Li J, Lobo CC, Lock EF, Lynch DR, Mareci TH, Martinez ARM, Monti S, Nigri A, Pandolfo M, Reetz K, Roberts TP, Romanzetti S, Rudko DA, Scaravilli A, Schulz JB, Subramony SH, Timmann D, França MC Jr, Harding IH, Rezende TJR; TRACK-FA Neuroimaging Consortium. Automated Deep Learning-based Segmentation of the Dentate Nucleus Using Quantitative Susceptibility Mapping MRI , Radiol Artif Intell .: 2025,e240478.

Yameogo P, Aguilar S, Prakash TP, Rigo F, Lynch DR, Napierala JS, Napierala M. Antisense oligonucleotide therapy for patients with Friedreich's ataxia carrying the c.165+5G>C splicing mutation. , Mol Ther Nucleic Acids. , 36(3): 2025,102617

Gunther, K, Profeta, V, Keita, M, Park, C, Wells, M, Sharma, S, Schadt, K Lynch, D. R. Safety Monitoring of Omaveloxolone in Friedreich Ataxia: Results from one year of clinical treatment , Neurology and Therapy, 14(3): 2025,1105-1114